Parkinson's Disease Clinical Trial
— DT-PDSAFExOfficial title:
Can Dual Task Walking Improve in Parkinson's Disease After External Focus of Attention Exercise? A Single Blind Randomized Controlled Trial
Verified date | August 2017 |
Source | Sun Life Financial Movement Disorders Research and Rehabilitation Centre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the underlying mechanism and influence of externally vs. internally focused exercise on rehabilitation in Parkinson's disease. The upcoming exercise intervention methodology will aim to meet the requirements of a 1A silver ranking level, single blind, randomized control trial according to the criterion of the Cochrane Musculoskeletal Review Group
Status | Completed |
Enrollment | 65 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Either gender, no age or location restriction - Diagnosed with idiopathic Parkinson's disease by a Neurologist - Able to stand 2 minutes, unassisted - Able to walk 10 meters, unassisted - Able to understand English instructions Exclusion Criteria: - A neurological disease other than Parkinson's disease - Peripheral neuropathy - Clinically diagnosed with dementia |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sun Life Financial Movement Disorders Research and Rehabilitation Centre |
Sage MD, Almeida QJ. Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease. Mov Disord. 2009 Jun 15;24(8):1132-8. doi: 10.1002/mds.22469. — View Citation
Wulf G, Landers M, Lewthwaite R, Töllner T. External focus instructions reduce postural instability in individuals with Parkinson disease. Phys Ther. 2009 Feb;89(2):162-8. doi: 10.2522/ptj.20080045. Epub 2008 Dec 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Unified Parkinson's disease Rating Scale Part III (UPDRS-III) | A physical movement assessment to quantify Parkinson's disease symptom severity. This is a non-invasive, risk free, painless examination. | Pre-assessment to post-assessment (12 weeks) | |
Primary | UPDRS-III | A physical movement assessment to quantify Parkinson's disease symptom severity. This is a non-invasive, risk free, painless examination. | Post-assessment to Washout (8 weeks) | |
Primary | Single and Dual Task Walking | Participants will be asked to walk along a 9.75m long and 0.61m wide ProtoKinetics Movement Analysis Software™ electronic walkway carpet (Zeno Walkway - ProtoKinetics, Havertown, PA, USA). This electronic walkway will measure spatiotemporal characteristics of the individuals' gait while they walk with and without the performance of a dual task. The dual task that will be performed by the participants with Parkinson's disease will be a phoneme monitoring dual task not trained in the intervention. Participants will be asked to complete 3 trials of each condition. | Pre-assessment to Post-assessment (12 weeks) | |
Primary | Single Task and Dual Task Walking | Participants will be asked to walk along a 9.75m long and 0.61m wide ProtoKinetics Movement Analysis Software™ electronic walkway carpet (Zeno Walkway - ProtoKinetics, Havertown, PA, USA). This electronic walkway will measure spatiotemporal characteristics of the individuals' gait while they walk with and without the performance of a dual task. The dual task that will be performed by the participants with Parkinson's disease will be a phoneme monitoring dual task not trained in the intervention. Participants will be asked to complete 3 trials of each condition. | Post-assessment to washout (8 weeks) | |
Primary | Parkinson Anxiety Scale Questionnaire | Valid measure of persistent, episodic, and avoidance behaviour anxiety | Pre-assessment to Post-assessment (12 weeks) | |
Primary | Parkinson Anxiety Scale Questionnaire | Valid measure of persistent, episodic, and avoidance behaviour anxiety | Post-assessment to washout (8 weeks) | |
Secondary | Measures of Executive Function | To measure general cognitive status, the Montreal Cognitive Assessment will be completed. | Pre-assessment to post-assessment (12 weeks) | |
Secondary | Measures of Executive Function | To measure general cognitive status, the Montreal Cognitive Assessment will be completed. | Post-assessment to Washout (8 weeks) | |
Secondary | Parkinson's disease Questionnaire 39 | A validated questionnaire for individuals with Parkinson's disease to address well-being and perceived quality of life. | Pre-assessment to Post-assessment (12 weeks) | |
Secondary | Parkinson's disease Questionnaire 39 | A validated questionnaire for individuals with Parkinson's disease to address well-being and perceived quality of life. | Post-assessment to washout (8 weeks) | |
Secondary | Community Health Activities Model Program for Seniors questionnaire (CHAMPS) | To determine whether the control group changes in physical activity level throughout the duration of the present study | Pre-assessment to post-assessment (12 weeks) | |
Secondary | CHAMPS | To determine whether the control group changes in physical activity level throughout the duration of the present study | Post-assessment to washout (8 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A |